

# The *Drosophila* gene *Start1*: A putative cholesterol transporter and key regulator of ecdysteroid synthesis

Guenter E. Roth\*, Mathias S. Gierl, Lars Vollborn, Martin Meise, Ruth Lintermann, and Guenter Korge

Institut fuer Biologie, Freie Universitaet Berlin, Arnimallee 7, 14195 Berlin, Germany

Communicated by Mark T. Groudine, Fred Hutchinson Cancer Research Center, Seattle, WA, December 12, 2003 (received for review September 19, 2003)

Human metastatic lymph node 64 (MLN64) is a transmembrane protein that shares homology with the cholesterol-binding vertebrate steroid acute regulatory protein (StAR)-related lipid transfer domain (START) and is involved in cholesterol traffic and steroid synthesis. We identified a *Drosophila melanogaster* gene whose putative protein product shows extensive homology with MLN64 and that we name *Start1* (FlyBase CG3522). The putative *Start1* protein, derived from *Start1* cDNA sequences, contains an additional 122 aa of unknown function within the StAR-related lipid transfer domain. Similar inserts seem to exist in the *Start1* homologues of *Drosophila pseudoobscura* and *Anopheles gambiae*, but not in the homologous protein of the urochordate *Ciona intestinalis*. Immunostaining using an insert-specific antibody confirms the presence of the insert in the cytoplasm. Whereas RT-PCR data indicate that *Start1* is expressed ubiquitously, RNA *in situ* hybridizations demonstrate its overexpression in prothoracic gland cells, where ecdysteroids are synthesized from cholesterol. Transcripts of *Start1* are detectable in embryonic ring gland progenitor cells and are abundant in prothoracic glands of larvae showing wave-like expression during larval stages. In adults, *Start1* is expressed in nurse cells of the ovary. These observations are consistent with the assumption that *Start1* plays a key role in the regulation of ecdysteroid synthesis. Vice versa, the expression of *Start1* itself seems to depend on ecdysone, as in the ecdysone-deficient mutant *ecd-1*, *Start1* expression is severely reduced.

In insects, pulses of ecdysteroid hormones induce larval molting and metamorphosis. Changes of puffing patterns in the polytene chromosomes in the course of the salivary gland development of *Drosophila melanogaster* had led Becker (1) to propose in 1962 a role for ecdysone in the regulation of gene expression. Since then, numerous reports have demonstrated that ecdysone is the dominant player in regulating cascades of gene activities, thereby controlling the major developmental events of insects. In *Drosophila*, we are beginning to understand at the molecular level how ecdysone induces gene expression (2).

Much less is known about the regulation of the synthesis of ecdysone itself and the generation of the wave-like diurnal change of the ecdysone titer during development. In the postembryonic developmental stages of insects, ecdysone is synthesized in the endocrine prothoracic gland (PG). In cyclorrhaphus diptera like *Drosophila*, the PG, the corpora allata, and the corpora cardiaca form the ring gland, which is innervated by the CNS (3). In Lepidoptera, prothoracicotrophic hormones (PTTH) are synthesized by neurosecretory cells of the CNS and act on the PG, thereby initiating a transducing cascade, which results in the up-regulation of ecdysteroid synthesis from its precursor cholesterol (4). PTTH activity has been found in brain extracts of several insect species like the lepidoptera *Bombyx mori* (5) and *Manduca sexta* (6); however, we are only beginning to identify the components of the transducing cascade.

In vertebrates, the regulation of steroid hormone synthesis is much better understood. Steroidogenic hormones like adrenocorticotrophic hormone are released from the pituitary, recognized by their target cell receptors, and regulate the expression

of genes involved in the steroid hormone pathway. The rate-limiting step in this pathway seems to be the induction of the synthesis of the steroid acute regulatory protein (StAR). StAR mediates, by means of the StAR-related lipid transfer (START) domain, the transfer of cholesterol across the mitochondrial membrane to the side-chain cleavage P<sub>450</sub> enzyme that converts cholesterol to pregnenolon (7). A similar function has been assigned to the vertebrate cholesterol transporter MLN64 (metastatic lymph node 64), which shares the START domain with the StAR protein but, in addition, has a transmembrane domain region (8).

Here, we describe a gene of *D. melanogaster*, *Start1*, as the likely homologue of MLN64. *Start1* seems to be the only gene in *Drosophila* that codes for a START domain protein of the StAR-type START subfamily (9). It is expressed in a spatial and temporal pattern consistent with it being the rate-limiting factor in ecdysteroidogenesis. On the other hand, our data indicate that the expression of *Start1* itself depends on ecdysone, implying that in *Drosophila* ecdysone might be involved in the regulation of its own synthesis. This possibility seems especially attractive to us, because for *Drosophila* a PTTH similar to *Bombyx* PTTH has not yet been identified, and the role of a *Drosophila* protein with PTTH-like activity (10) remains open.

## Materials and Methods

**Computer Analyses.** BLAST searches were performed at the Berkeley *Drosophila* Genome Project (BDGP) server ([www.fruitfly.org/blast/](http://www.fruitfly.org/blast/)). BLASTP, matrix BLOSUM 52, the Predicted Proteins database, and human StAR (GenBank accession no. P49675) as a query sequence led to CG3522 ( $P = 10^{-15}$ ).

*Start1* homologues in the genomes of *Drosophila pseudoobscura*, *Anopheles gambiae*, and *Ciona intestinalis* were detected by TBLASTN, and the *D. melanogaster Start1* cDNA or protein sequence as a query. The amino acid sequence for *D. pseudoobscura* is derived from contig 5050 by analyzing nucleotides 16.001 to 19.000 by GeneMark.hmm (<http://opal.biology.gatech.edu/GeneMark/hmmchoice.html>). The *A. gambiae* genomic *Start1* sequence (GenBank accession no. EAA03945) contained a gap and was completed (see below). *C. intestinalis Start1* homologous protein is contained in the Scaffold 100 sequence ([www.jgi.doe.gov/](http://www.jgi.doe.gov/)) within nucleotides 221032 and 228458.

CLUSTAL W (version 1.8.1) was used for protein alignment; TOPPED2 was used for transmembrane prediction.

**Stocks.** *D. melanogaster* strains Kochi-R and *ecd-1* (obtained from C. Thummel, University of Utah, Salt Lake City) were kept on

Abbreviations: PG, prothoracic gland; BDGP, Berkeley *Drosophila* Genome Project; StAR, steroid acute regulatory protein; START, StAR-related lipid transfer; ICS, insert coding sequence; PTTH, prothoracicotrophic hormones; PBR, peripheral benzodiazepine receptor; MLN64, metastatic lymph node 64.

Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. AY455866).

\*To whom correspondence should be addressed. E-mail: [groth@genetik.fu-berlin.de](mailto:groth@genetik.fu-berlin.de).

© 2004 by The National Academy of Sciences of the USA

cornmeal medium at 25°C. For age-staging of third instar larvae, the medium was supplemented by bromophenol blue (11). Kc cells were provided by H. Saumweber, Humboldt-Universität, Berlin.

**Cloning and RT-PCR.** cDNA clones LD23890, RE28156, and RE40430 were obtained from BDGP. Plasmid pStart1179 was constructed by amplifying a 1,179-bp fragment by RT-PCR using total RNA from *D. melanogaster* third instar larvae and primers Start4 (5'-GCCTGGTTCTGGACTGTAG) and Start5 (5'-CAGTTCGTTGACATGCTTGC). The fragment was cloned into pGEM-T (Promega) and sequenced.

A 332-bp DNA fragment coding for part of the putative Start1 protein insert was amplified from pStart1179, using primers Start10 (5'-ccaagaattcCAATGGTCAAATCTGCGATG) containing an *EcoRI* site (lowercase letters), and Start11 (5'-ccaactcgagTCGTCATGTTATTTCGCTTTCG) containing an *XhoI* site, cloned into pBlueScript II SK(-) and sequenced. A 1,204-bp sequence covering the transmembrane region of *Start1* was cloned into pGEM-T by using primers Start25 (5'-GCATTCGGTGTTCCTTTTGT) and Start26 (5'-CCCTA-CAGTCCAGGAACCAG).

To fill a gap within the *Start1* gene of the *A. gambiae* genome sequence, we amplified and sequenced this region (*A. gambiae* DNA was provided by F. Kafatos, European Molecular Biology Laboratory, Heidelberg). This replaces C<sub>11</sub> N<sub>20</sub> at position 7457741 of the National Center for Biotechnology Information sequence AAAB01008807.1 by 5'-C<sub>7</sub>ACAGGCCTACACA, thereby producing an acceptor splice site (BDGP splice site prediction,  $P = 0.95$ ), and leads to the given amino acid sequence.

RNA was isolated by TRIzol reagent (Invitrogen). For RT-PCR, the OneStep RT-PCR kit (Qiagen, Valencia, CA) and primers Start4 and Start5 were used.

*D. melanogaster* cDNA libraries were constructed from RNA of third instar larvae (Clontech) or brain/ring glands (12).

**Northern Analysis.** Poly(A) RNA was prepared from brain/ring gland complexes of third instar larvae by using MESSAGE MAKER (GIBCO), separated in a 1% agarose/formaldehyde gel and transferred to a Nytran Super Charge membrane (Schleicher and Schuell). A [<sup>32</sup>P]UTP-labeled *Start1* antisense RNA probe was synthesized from a subclone of cDNA RE28156. By primers Start13 (5'-ccaactcgagCTGAACCTCGCTCTCCTGCTT) and Start14 (5'-ccaagaattcAATATAACCGCTCGCATGT), a 1,882-bp fragment containing exons 1–10 was amplified and cloned into pBlueScript SK(-) as an *EcoRI/XhoI* (lowercase letters in the primers) fragment. To reduce the length of the transcribed polylinker, it was again subcloned into pGEM-9Zf(-) (Promega) as a *SalI/XbaI* fragment. Hybridization was carried out in a roll oven. X-Omat AR (Kodak) and Biomax MS screens (Kodak) were used for exposure.

**Whole-Mount *In Situ* Hybridization.** Digoxigenin-labeled sense and antisense RNA probes were synthesized by using the DIG RNA labeling kit (Roche Molecular Biochemicals). An *EcoRI/SalI* fragment containing the 5' sequence up to nucleotide 1,736 of cDNA LD23890 was excised from pOT2, subcloned in pBlueScript SK(-), and used for all experiments, except for ovaries where the transmembrane domain clone was used. For hybridization of embryos we used formaldehyde for fixation (13). Hybridization of larval and adult tissue was done as given in ref. 14, except that tissue was digested with Pepsin. Probe was detected by an anti-digoxigenin-alkaline phosphatase antibody (Roche Molecular Biochemicals), nitroblue tetrazolium, and 5-bromo-4-chloro-3-indolyl phosphate.

**Antibodies and Immunostaining.** For polyclonal antibody production, two regions of *Start1* were expressed in *Escherichia coli*.


Region S comprises only the START domain with insert (amino acids 228–572). It was amplified by primers Start17 (5'-gggggcatATGGACACGGCTCGTCAT) containing an *NdeI* site and Start16 (5'-ccccctcgagCTTCTGCCTCAGTTCGTT) containing an *XhoI* site. Region I comprises the insert only (amino acids 363–465), amplified by primers Start10 (see above) and Start19 (5'-ccccctcgagGTCGACCTTGTCTTAGC) containing an *XhoI* site. Fragments were cloned into pET21b (Invitrogen) and sequenced. Start1 protein was purified by His-tag columns. Rabbits were immunized by Eurogentec (Brussels). Whole-mount immunostaining was done as described (15) by using goat anti-rabbit Cy3-labeled secondary antibody (Jackson ImmunoResearch). Preparations were examined with a Zeiss Axiophot fluorescence microscope and a Quantix (Photometrics, Tucson, AZ) video camera. Images were processed by an Apple computer and PHOTOSHOP 5 (Adobe Systems, Mountain View, CA).

## Results

**Insect START Domain Proteins Related to Vertebrate MLN64 Contain an Unusual Insert.** A computer search of the *D. melanogaster* genome for the existence of cholesterol transport proteins, using the START domain of the human StAR protein as the query sequence, leads to only one significant hit, a gene annotated by the BDGP as CG3522 and that we name *Start1*. Further comparisons revealed that the putative Start1 protein is more closely related to the vertebrate cholesterol transporter MLN64 than to StAR by having four putative transmembrane helices in addition to the START domain. The predicted START domain of the *D. melanogaster* Start1 protein differs from the vertebrate START domains by containing an insert of 122 aa (Fig. 1). The bipartite structure of the START domain is indicated by a National Center for Biotechnology Information conserved domain search, which places part I to amino acids 262–362 and part II to amino acids 487–574 (Pfam *E* value 10<sup>-7</sup> for both parts). According to the BDGP prediction, *Start1* consists of 12 exons, with the sequence coding for the 122-aa insert (insert coding sequence, ICS) contained within exon 10. Because the ICS is flanked by weak splice sites, we verified its existence in mRNA and protein. (i) Sequence analysis of the BDGP reference cDNA for CG5322, LD23890, revealed that it contains a splice artifact at the exon 10/exon11 junction, being not suited to clarify the problem. Therefore, we cloned by RT-PCR a DNA fragment (pStart1179) covering exon 10. The sequence of this fragment and its fusion with the 5' and 3' adjacent fragments of LD23890 leads to a virtual cDNA with a conceptual translation product containing the insert in accordance with the BDGP prediction. (ii) We sequenced other BDGP cDNAs, RE28156 and RE40430. Both contain the ICS. (iii) By PCR analysis of different cDNA libraries and RT-PCR on RNA from different tissues (see below), we did not obtain fragments without ICS. (iv) RNA *in situ* hybridization and immunostaining indicate the existence of the insert (see below). (v) In the genome databases of *D. pseudoobscura*, *A. gambiae*, and the urochordate *C. intestinalis*, we identified their *Start1* homologues (Fig. 1). Both insect genes, but not the one of *Ciona*, contain an insert related to that of *D. melanogaster*. In both cases, we did not detect putative splice sites adjacent to the insert. In sum, we conclude that the amino acid insert is a native component of Start1 protein.


**Sequence Comparison.** Amino acid sequence comparison of the proteins aligned as in Fig. 1 leads to 22% identity and 52% similarity between the five species. The degree of conservation is highest for the putative transmembrane helices-containing domain (55% identity for transmembrane 1) and the START domain. The transmembrane domain has been shown to be necessary for endosomal location of MLN64, but does not seem to contain conventional endosomal targeting signals (16). Our





**Fig. 3.** *Start1* is expressed in nurse cells of ovaries and the prothoracic cells of the ring gland. Whole-mount RNA *in situ* hybridization using digoxigenin-labeled *Start1* antisense RNA as a probe is shown. (A) Ovariols with egg chambers; nurse cells of stage 10 egg chambers show staining. (B) Praeblastoderm. (C) Blastoderm. (D) Embryo, stage 16; the strongly stained cells are the presumed precursor cells of the PG. (E–J) Brain/ring gland complexes from first larval instar (E) and second larval instar (F). (G–I) third larval instar of different stages: freshly hatched larva (G), feeding larva (H), nonfeeding/crawling larva (I), and white prepupa (J). The difference in expression between the second larva (F) and the young third larva (G) indicates that *Start1* transcription is shut off during hatching. Staining conditions were kept constant for all larval stages. No staining was obtained for the sense RNA probes (data not shown). rg, ring gland; b, brain; vg, ventral ganglion. Arrowhead in I indicates unstained corpus allatum cells. (Bar, 40  $\mu$ m.)

During development, *Start1* RNA is found in praeblastoderm and blastoderm embryos, reflecting maternal mRNA. *Start1* is specifically expressed in the PG cells of the ring gland of the three larval instars and its presumed embryonic precursor cells. A specific staining of the embryo is observed earliest at stage 16. A precise analysis of the level of expression of *Start1* throughout larval development reveals that *Start1* RNA is abundant at the



**Fig. 4.** Northern analysis of *Start1*. Two micrograms of poly(A) RNA from brain/ring gland complexes was size-fractionated by gel electrophoresis, transferred to a membrane, and hybridized with a  $^{32}$ P-labeled RNA probe complementary to *Start1*. Exposure time was 14 h. Lines show the position of the high range RNA ladder marker bands (Fermentas; sizes are in kb). The bulk of the signal appears at  $\approx$ 2.4 kb, as expected for *Start1* transcripts, including 100 nt of poly(A) tail. No signal is detected at 2.1 kb, the approximate size for transcripts without the 366-nt ICS. As yet, we have no conclusive explanation for the origin of the other bands.

end of both the second and third instar, but is almost undetectable in freshly hatched third instar larvae and declines in white prepupae, exhibiting a development-related wave-like diurnal pattern of expression (Fig. 3). Besides the PG cells, no other larval cells show significant *Start1* RNA signals.


The PG cells of the ring gland are the predominant source of ecdysteroids in *Drosophila* postembryonic development, synthesized in a wave-like manner. In addition, there is growing evidence that the ovary is the source of ecdysteroids in adults (4, 17). Therefore, the observed spatial and temporal pattern of expression of *Start1* and its probable involvement in the transport of cholesterol infer that *Start1* is involved in the synthesis of ecdysteroids.

***Start1* Protein Can Be Detected in PG Cells.** The presence of the ICS in cDNAs and RT-PCR products had indicated that the insert exists in the *Start1* protein. Further experiments support this conclusion. First, *in situ* hybridization using an ICS-specific antisense RNA probe resulted in hybridization signals in the cytoplasm of PG cells (data not shown). Second, Northern analysis using RNA from brain/ring gland complexes leads to a band, the size of which equals the expected size for *Start1* mRNA containing the ICS (Fig. 4). Third, an antibody, directed specifically against the amino acid sequence of the insert, stains PG cells (Fig. 5) in the same way as an antibody against the START domain including the insert (data not shown), also indicating that *Start1* mRNA is readily translated into protein.

***Start1* Expression Seems to Depend on Ecdysone.** The temperature-sensitive mutant *ecd-1* has a reduced titer of ecdysone after a shift from 20°C to 29°C early in the third larval instar stage. Such larvae have only 5% of the WT ecdysone titer at pupariation and do not pupariate (18). Analysis of *Start1* expression of WT and *ecd-1* larvae by *in situ* hybridization demonstrates a severely reduced amount of *Start1* transcripts in the mutant at the restrictive temperature (Fig. 6). The level of expression in the WT at 29°C seems to be normal; however, compared to 20°C, there is a change in the subcellular distribution of *Start1* transcripts. In the mutant, even at 20°C the hybridization signals are different from those in the WT, concerning both intensity and subcellular distribution. At 29°C in the mutant, most of the PG cells do not show hybridization signals at all (Fig. 6D).

## Discussion


The family of START domain proteins is believed to function in the intracellular transport of lipids, lipid metabolism, and cell



**Fig. 5.** Immunofluorescence detection of Start1 protein in the PG cells. As primary antibody we used a polyclonal antibody risen against the insert amino acid sequence. The secondary antibody was labeled with Cy3. There was no noticeable difference in staining with antibodies against the complete START domain, without the transmembrane domains (data not shown). Besides the PG cells, no other tissue showed prominent staining.

signaling (19). The START protein characterized best is the mammalian StAR protein, which transfers cholesterol, the precursor for steroid hormones, to mitochondria in steroidogenic cells (7). In the human and mouse genomes, 15 genes have been identified that encode START domain proteins. Some of these contain only START; in others, START is combined with other domains. A phylogenetic analysis divides this protein family into six subfamilies (9). According to this computer analysis, the *Drosophila* genome has members of only three subfamilies. Our own data indicate and are in agreement with ref. 9 that *Start1* is the only START domain-coding gene in the *Drosophila* genome that belongs to the StAR subfamily. However, *Start1* is not homologous to StAR itself, which contains only the START domain, but is homologous to *MLN64*, which in addition to the START domain carries a domain with four putative transmembrane helices.

To test our negative computer search for a homologue of *StAR*, we performed nonstringent genomic Southern hybridizations, using *Start1* as a probe, but did not detect DNA fragments, indicating the existence of a related gene (data not shown). This



**Fig. 6.** *Start1* expression in the PG cells is reduced in the temperature-sensitive ecdysone-deficient mutant *ecd-1*. Animals were kept at 20°C, the permissive temperature for *ecd-1*, up to the late second instar. Then one group was allowed to continue development at 20°C, whereas the other group was transferred to 29°C, the restrictive temperature for *ecd-1*. RNA *in situ* hybridization was performed on late third instar larvae. WT strain Kochi-R is shown at 20°C (A) and 29°C (B). At this temperature nuclei also show staining. *ecd-1* kept at 20°C (C) and 29°C (D) is shown. In *ecd-1* at 29°C ring glands are smaller compared to 20°C as observed (35). Only some of the ring glands in the preparation showed staining, and in those only a few cells are stained.

result is especially critical because of the finding that the START domain of *Start1* of *D. melanogaster* is different from all other START domains known so far by containing a 122-aa insert. The structure of the *Start1* homologues of *D. pseudoobscura* and *A. gambiae* are similar (Fig. 1). Both StAR and MLN64 have been shown to bind cholesterol by means of their START domain. X-ray crystal structures imply that the START domain forms a cavity, accommodating a single cholesterol molecule (20).

We show that the insert in *D. melanogaster* exists in the translation product of *Start1*. Analysis of cDNAs, RT-PCR, whole cDNA libraries, Northern analysis, insert-specific *in situ* hybridization, and finally immunostaining with insert-specific antibodies indicate its presence in the Start1 protein. So far, we do not know whether the insert influences the function of Start1 with respect to the formation of the cavity.

*MLN64*, which was originally isolated by its overexpression and coamplification with the *ERBB2* oncogene in human breast cancers, is expressed in all tissues and probably plays a role in intracellular sterol trafficking (8, 21). In addition, it is supposed to be involved in the synthesis of steroid hormones in the placenta (22). The expression pattern, which we observe for *Start1*, is similar to that of *MLN64* in mammals. It is found expressed ubiquitously, obviously also in nonsteroidogenic tissues, when analyzed by RT-PCR (Fig. 2), but is found heavily expressed in the steroidogenic PG when analyzed by *in situ* hybridization (Fig. 3). Possibly the level of expression in the other tissues is too low to be detected by *in situ* hybridization.

*MLN64* has been found localized on late endosomes and lysosomes, which are involved in cholesterol trafficking. The N-terminal region containing the transmembrane helices is necessary for this location (16). The degree of conservation of this region between the proteins is striking. Residues found to be essential for the endosomal location are conserved in Start1 (Fig. 1), indicating an identical location and similar function in *Drosophila* cells.

It was supposed earlier that in steroidogenic placental tissue MLN64 might deliver cholesterol to mitochondria. This view was supported by the finding of fragments of MLN64 containing the START domain in placental mitochondria, implying proteolytic cleavage of MLN64 (23). In addition, it was demonstrated in an *in vitro* system that the MLN64 START domain transfers cholesterol from liposomes to mitochondrial membranes (24). For insects, there is evidence that, like in mammals, cholesterol has to get into mitochondria for the synthesis of ecdysteroids. Recently, two mitochondrial cytochrome P450 monooxygenases required for the production of ecdysone have been described for *Drosophila* (25).

Given these data on *MLN64* and in view of the similarities between *Start1* and *MLN64* in sequence and expression pattern, we are convinced that *Start1* plays a role in insects analogous to that of *MLN64* in mammals.

There is evidence for the involvement of human peripheral benzodiazepine receptor (PBR) in steroidogenesis (26), and there are indications that StAR protein and PBR interact at mitochondrial membranes (27). This finding led to speculation about the possible involvement of an insect PBR in ecdysteroidogenesis (4). The *Drosophila* protein most closely related to human PBR is the predicted protein product of gene CG2789 (DmPBR) showing 47% identity. We amplified a fragment of CG2789 and used this for RNA *in situ* hybridization with embryos, with brain/ring gland complexes of third instar larvae, and with adult ovaries. None of these experiments yielded a significant hybridization signal (data not shown). However, RT-PCR is positive with RNA, both from third larval instar brain/ring gland complexes and the carcass (data not shown). These data do not support a model in which Start1 and DmPBR would interact in insect steroidogenic tissue, as one would expect DmPBR to be hyperexpressed in the PG.

The expression pattern of *Start1*, in combination with its possible dependence on ecdysone, has some implications on the view of how the synthesis of ecdysone might be regulated during *Drosophila* development. There is evidence that in adult *Drosophila* females ecdysteroids are synthesized in the ovary (17), and it was suggested that nurse cells are the site of ecdysteroid synthesis, as the activation of ecdysteroid-dependent genes was observed in these cells (28). In consistency, we observe expression of *Start1* in nurse cells. This observation agrees well with the nurse cell expression of *dare*, which codes for a mitochondrial protein transporting electrons to P450 enzymes and was shown to be necessary for ecdysteroidogenesis (29). However, the genes *shadow* (*sad*) (25) and *disembodied* (*dib*) (30), which encode hydroxylases involved in the conversion of cholesterol to ecdysteroids, are expressed in follicle cells. In conclusion, it seems likely that the mRNAs of the four genes are transported into the oocyte where ecdysteroids could be synthesized to be used in embryogenesis. The existence of such maternal ecdysteroids has been proposed (31). It remains to be analyzed if the activation of *Start1* in nurse cells depends on ecdysteroids.

Besides this function for *Start1*, we think that part of the ovarian *Start1* mRNA is stored in the oocyte as maternal mRNA. This is inferred from the observation of considerable staining of preblastoderm and blastoderm embryos after *in situ* hybridization (Fig. 3). The existence of maternal transcripts has also been reported for *sad* (25) and *dib* (30) and was postulated for *dare* (29). Maternal mRNA was also found from the *Drosophila* gene *woc* encoding a transcription factor involved in ecdysone bio-

synthesis (32). Translation of these maternal mRNAs would explain the surge in ecdysteroids, which has its peak at stages 11–12, well before the formation of the embryonic ring gland at stage 15, where at this stage *sad* and *dib* and, as shown here, *Start1* are activated. So far, there are no data on the embryonic activation of *dare*. We suppose that the coordinated activation of these genes of the steroidogenic pathway initiates the next wave of ecdysteroids. How are the pulses of ecdysteroids generated? We observe a cycling of expression of *Start1* in the second and third larval instar. The same cycling was found for *sad* and *dib* (25). Given the seeming dependency of *Start1* on ecdysteroids, it is tempting to speculate that the two cycles might drive each other. A PTTH-like activity could connect these cycles to the circadian rhythm.

Presently, we cannot rule out that the weak expression of *Start1* in the *ecd-1* mutant has other reasons but the reduced ecdysone level. However, additional observations support our idea that *Start1* regulation depends on ecdysone. One of the transcription factors regulating the *StAR* gene is steroidogenic factor-1 (SF-1) (33). The *D. melanogaster* homologue of SF-1 is the transcription factor  $\beta$ FTZ-F1. As (i) *Start1* contains two possible binding sites for  $\beta$ FTZ-F1, (ii)  $\beta$ FTZ-F1 is expressed in PG cells (G.E.R., unpublished results) and (iii)  $\beta$ FTZ-F1 is controlled by ecdysone (34), we think that ecdysone is indeed a good candidate to regulate *Start1*.

We thank two unknown reviewers for helpful comments on the manuscript. This work was financially supported as a Pilot Project by the Freie Universitaet Berlin (to G.E.R.).

1. Becker, H. J. (1962) *Chromosoma* **13**, 341–384.
2. Thummel, C. S. (2002) *Insect Biochem. Mol. Biol.* **32**, 113–120.
3. Siegmund, T. & Korge, G. (2001) *J. Comp. Neurol.* **431**, 481–491.
4. Gilbert, L. I., Rybczynski, R. & Warren, J. T. (2002) *Annu. Rev. Entomol.* **47**, 883–916.
5. Nagasawa, H., Guo, F., Zhong, X. C., Xia, B. Y., Wang, Z. S., Qui, X. J., Wei, D. Y., Chen, E. I., Wang, J. Z., Suzuki, A., et al. (1980) *Sci. Sin. Ser. A* **23**, 1053–1060.
6. Bollenbacher, W. E., Katahira, E. J., O'Brien, M., Gilbert, L. I., Thomas, M. K., Agui, N. & Baumhover, A. H. (1984) *Science* **224**, 1243–1245.
7. Stocco, D. M. (2001) *Annu. Rev. Physiol.* **63**, 193–213.
8. Moog-Lutz, C., Tomasetto, C., Regnier, C. H., Wendling, C., Lutz, Y., Muller, D., Chenard, M. P., Basset, P. & Rio, M. C. (1997) *Int. J. Cancer* **71**, 183–191.
9. Soccio, R. E. & Breslow, J. L. (2003) *J. Biol. Chem.* **278**, 22183–22186.
10. Kim, A. J., Cha, G. H., Kim, K., Gilbert, L. I. & Lee, C. C. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 1130–1135.
11. Andres, A. J. & Thummel, C. S. (1994) *Methods Cell Biol.* **44**, 565–573.
12. Grams, R. & Korge, G. (1998) *Gene* **215**, 191–201.
13. Tautz, D. & Pfeifle, C. (1989) *Chromosoma* **98**, 81–85.
14. Wolf, T. (2000) in *Drosophila Protocols*, eds. Sullivan, W., Ashburner, M. & Hawley, R. S. (Cold Spring Harbor Lab. Press, Plainview, NY), pp. 201–227.
15. Ito, K., Urban, J. & Technau, G. M. (1995) *Roux's Arch. Dev. Biol.* **204**, 284–307.
16. Alpy, F., Stoeckel, M. E., Dierich, A., Escola, J. M., Wendling, C., Chenard, M. P., Vanier, M. T., Gruenberg, J., Tomasetto, C. & Rio, M. C. (2001) *J. Biol. Chem.* **276**, 4261–4269.
17. Riddiford, L. M. (1993) in *The Development of Drosophila melanogaster*, eds. Bate, M. & Martinez-Arias, A. (Cold Spring Harbor Lab. Press, Plainview, NY), Vol. 2, pp. 899–939.
18. Garen, A., Kauvar, L. & Lepesant, J. A. (1977) *Proc. Natl. Acad. Sci. USA* **74**, 5099–5103.
19. Ponting, C. P. & Aravind, L. (1999) *Trends Biochem. Sci.* **24**, 130–132.
20. Tsujishita, Y. & Hurley, J. H. (2000) *Nat. Struct. Biol.* **7**, 408–414.
21. Tomasetto, C., Regnier, C., Moog-Lutz, C., Mattei, M. G., Chenard, M. P., Lidereau, R., Basset, P. & Rio, M. C. (1995) *Genomics* **28**, 367–376.
22. Strauss, J. F., III, Kishida, T., Christenson, L. K., Fujimoto, T. & Hiroi, H. (2003) *Mol. Cell. Endocrinol.* **202**, 59–65.
23. Watari, H., Arakane, F., Moog-Lutz, C., Kallen, C. B., Tomasetto, C., Gerton, G. L., Rio, M. C., Baker, M. E. & Strauss, J. F., III (1997) *Proc. Natl. Acad. Sci. USA* **94**, 8462–8467.
24. Zhang, M., Liu, P., Dwyer, N. K., Christenson, L. K., Fujimoto, T., Martinez, F., Comly, M., Hanover, J. A., Blanchette-Mackie, E. J. & Strauss, J. F., III (2002) *J. Biol. Chem.* **277**, 33300–33310.
25. Warren, J. T., Petryk, A., Marques, G., Jarcho, M., Parvy, J. P., Dauphin-Villemant, C., O'Connor, M. B. & Gilbert, L. I. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 11043–11048.
26. Beurdeley-Thomas, A., Miccoli, L., Oudard, S., Dutrillaux, B. & Poupon, M. F. (2000) *J. Neurooncol.* **46**, 45–56.
27. West, L. A., Horvat, R. D., Roess, D. A., Barisas, B. G., Juengel, J. L. & Niswender, G. D. (2001) *Endocrinology* **142**, 502–505.
28. Kozlova, T. & Thummel, C. S. (2000) *Trends Endocrinol. Metab.* **11**, 276–280.
29. Freeman, M. R., Dobritsa, A., Gaines, P., Segraves, W. A. & Carlson, J. R. (1999) *Development (Cambridge, U.K.)* **126**, 4591–4602.
30. Chavez, V. M., Marques, G., Delbecque, J. P., Kobayashi, K., Hollingsworth, M., Burr, J., Natzle, J. E. & O'Connor, M. B. (2000) *Development (Cambridge, U.K.)* **127**, 4115–4126.
31. Bownes, M., Shirras, A., Blair, M., Collins, J. & Coulson, A. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 1554–1557.
32. Warren, J. T., Wismar, J., Subrahmanyam, B. & Gilbert, L. I. (2001) *Mol. Cell. Endocrinol.* **181**, 1–14.
33. Stocco, D. M., Clark, B. J., Reinhart, A. J., Williams, S. C., Dyson, M., Dassi, B., Walsh, L. P., Manna, P. R., Wang, X. J., Zeleznik, A. J. & Orly, J. (2001) *Mol. Cell. Endocrinol.* **177**, 55–59.
34. Woodard, C. T., Baehrecke, E. H. & Thummel, C. S. (1994) *Cell* **79**, 607–615.
35. Dai, J. D., Henrich, V. C. & Gilbert, L. I. (1991) *Cell Tissue Res.* **265**, 435–445.